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Genetic variants including 
markers from the exome chip and 
metabolite traits of type 2 diabetes
Susanne Jäger1,2, Simone Wahl2,3,4, Janine Kröger1,2, Sapna Sharma2,3,4, Per Hoffmann  5,6,7, 
Anna Floegel8, Tobias Pischon9,10,11, Cornelia Prehn  12, Jerzy Adamski  2,12,13, Martina 
Müller-Nurasyid14,15,16, Melanie Waldenberger3,4, Konstantin Strauch14,17, Annette Peters2,3,16, 
Christian Gieger3,4, Karsten Suhre  18, Harald Grallert2,3,4, Heiner Boeing8, Matthias B. 
Schulze1,2 & Karina Meidtner  1,2
Diabetes-associated metabolites may aid the identification of new risk variants for type 2 diabetes. 
Using targeted metabolomics within a subsample of the German EPIC-Potsdam study (n = 2500), 
we tested previously published SNPs for their association with diabetes-associated metabolites and 
conducted an additional exploratory analysis using data from the exome chip including replication 
within 2,692 individuals from the German KORA F4 study. We identified a total of 16 loci associated with 
diabetes-related metabolite traits, including one novel association between rs499974 (MOGAT2) and a 
diacyl-phosphatidylcholine ratio (PC aa C40:5/PC aa C38:5). Gene-based tests on all exome chip variants 
revealed associations between GFRAL and PC aa C42:1/PC aa C42:0, BIN1 and SM (OH) C22:2/SM C18:0 
and TFRC and SM (OH) C22:2/SM C16:1). Selecting variants for gene-based tests based on functional 
annotation identified one additional association between OR51Q1 and hexoses. Among single genetic 
variants consistently associated with diabetes-related metabolites, two (rs174550 (FADS1), rs3204953 
(REV3L)) were significantly associated with type 2 diabetes in large-scale meta-analysis for type 2 
diabetes. In conclusion, we identified a novel metabolite locus in single variant analyses and four genes 
within gene-based tests and confirmed two previously known mGWAS loci which might be relevant for 
the risk of type 2 diabetes.
Up to now numerous common risk variants (MAF ≥ 5%) for type 2 diabetes were identified by genome-wide 
association studies (GWAS)1, 2. However, they only explain a small proportion of the population variance1, 2. 
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To address this missing heritability, current studies concentrate on rare variants with potentially strong effects. 
One study identified four low frequency and rare variants which were associated with risk of type 2 diabetes3. 
Furthermore, the CHARGE consortium used exome chip variants from 23 different studies and found a novel 
association of a low-frequency nonsynonymous variant in the GLP1R with type 2 diabetes by an initial explor-
atory analysis of fasting glucose and insulin and a subsequent analysis of significant results for association with 
type 2 diabetes4. Similarly, metabolites associated with the risk of type 2 diabetes may aid the identification of 
new type 2 diabetes risk variants5. GWAS of metabolomics datasets (mGWAS) identified several so-called genet-
ically influenced metabotypes (GIMs)6–10 that show large genetic effect sizes explaining 10–20% of the observed 
variance in the metabolite traits11. In the current study population (EPIC-Potsdam), 14 single metabolites have 
been identified to be independently associated with risk of type 2 diabetes12. Two metabolite factors (principal 
components) largely explained the variance in metabolite traits and were associated with risk of type 2 diabetes 
in opposing directions12. Within this study, we aim to identify genetic variants which are associated with those 
previously identified diabetes-related metabolite traits12 and test for their association with type 2 diabetes risk. To 
do so, we firstly, investigated selected known mGWAS loci7, 8 for their association with diabetes-related metabolite 
traits (Fig. 1). Secondly, we conducted an exploratory analysis using HumanExome v1.1 Bead Array data to addi-
tionally explore the association of low-frequency (1% < MAF < 5%) and rare genetic variants (MAF < 1%) which 
were not captured by classical GWAS arrays (Fig. 1). Finally, we analyzed the associations between single genetic 
variants identified for being associated with diabetes-associated metabolite traits and risk of type 2 diabetes.
Results
All primary analyses have been carried out within the EPIC-Potsdam study with up to 2932 participants within 
the diabetes analyses (Fig. 1). Results of exploratory analyses were replicated in the KORA F4 study with up to 
2692 participants (Fig. 1). Baseline characteristics of both study populations can be found in Supplementary 
Table S1.
Eleven known mGWAS loci were associated with diabetes-related metabolite traits. We ana-
lyzed the association of 19 known mGWAS loci with 106 diabetes-associated metabolite traits (Fig. 1). These 
metabolite traits included single metabolites (n = 14), metabolite ratios defined on the basis of the observed 
metabolite network (n = 90) and two metabolite factors derived from PCA of diabetes-associated metabolites12.
Eleven of the 19 candidate SNPs from previous studies were associated with diabetes-related metab-
olite traits (P < 4.31 × 10−5) in EPIC-Potsdam (Supplementary Table S2). The SNP rs174547 (FADS1) 
Figure 1. Flowchart of the analytical strategy. The red circles indicate diabetes-associated metabolites and grey 
circles depict other metabolites. The colored squares indicate data sources used in the different steps of the 
analysis. GWAS, genome-wide association study; MAF, minor allele frequency; QC, quality control; SNP, single 
nucleotide polymorphism.
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was significantly associated with 36 single metabolite traits which primarily originate from the groups of 
acyl-alkyl-phosphatidylcholines and diacyl-phosphatidylcholines. Further statistically significant associa-
tions were found for rs9393903 (ELOVL2), rs7156144 (PLEKHH1), rs12641551 (ACSL1), rs272893 (SLC22A4/ 
OCTN1), rs603424 (SCD) and phosphatidylcholine ratios. Rs715 (CPS1), rs541503 (PHGDH) and rs1718306 
(PAH) were associated with amino acids. Rs11158519 (SYNE2), rs364585 (SPTLC3) and rs603424 (SCD) were 
related to ratios of sphingomyelins. Previous reports for genotype-by-sex-interactions of rs715 (CPS1) indicating 
larger effects in women than in men were confirmed in EPIC-Potsdam (Supplementary Table S3)
Exploratory analysis using exome chip data identified one novel locus for diabetes-associated 
metabolite traits. We carried out an exploratory analysis of all common (MAF ≥ 5%), low-frequency 
(1% ≤ MAF < 5%) and rare variants (MAF < 1%) with an allele frequency above 0.5% (n ≈ 42.000) for association 
with 106 diabetes-related metabolite traits (Fig. 1). The analysis revealed twelve loci that were associated with one 
or multiple metabolite traits (Supplementary Table S4). As the exome chip includes previously published GWAS 
hits, some of our results from the exploratory analysis overlap with findings from our candidate gene studies by 
representing the same locus (FADS1, CPS1, SGPP1/SYNE2) or the same SNP (rs12641551(ACSL1), rs364585 
(SPTLC3)). For overlapping results between candidate and exploratory analyses we calculated models including 
all associated SNPs (from candidate and exploratory analysis) at each locus for the top associated metabolite trait 
to identify independent signals (Supplementary Table S5). The exome chip variant rs174550 (FADS1) showed 
stronger associations with the PC aa C36:3/PC aa C36:4 ratio than the previously known mGWAS SNP rs174547 
on the FADS1 locus (Supplementary Table S5). An intergenic exome chip variant on chromosome 2 (rs4672596) 
near the previously identified CPS1 locus was associated with levels of glycine and the ratio of glycine and ser-
ine (Supplementary Table S4). However, the previously identified mGWAS SNP rs715 showed stronger associ-
ations in analyses on glycine levels (Supplementary Table S5). One low-frequency variant from the exome chip 
(rs12881815 located within SYNE2 with MAF = 4.8%) showed significant associations with two sphingomyelin 
ratios (SM C16:1/PC aa C28:1 and SM (OH) C22:2/SM (OH) C14:1) (Supplementary Table S4). However, in 
analyses including all three variants on SYNE2 (Supplementary Table S5) with the SM C16:1/PC aa C28:1 ratio, 
the exome chip variant rs7157785 (SGPP1) showed stronger effects than rs12881815 (SYNE2) and stronger effects 
than the previously identified mGWAS SNP (rs11158519 (SYNE2)).
We aimed to replicate suggestive significant findings from EPIC-Potsdam (P < 1.64 × 10−7) in the KORA F4 
study. Meta-analysis of results from both studies revealed six significant loci (P < 4.55 × 10−3) associated with one 
or multiple metabolite traits (Table 1). Among them was one novel locus, rs499974 (MOGAT2), that was associ-
ated with the ratio of PC aa C40:5/PC aa C38:5 (P = 6.88 × 10−15). The most deleterious variants identified within 
this study were located in APOE (CADD = 30.0) and REV3L (CADD = 32.0).
As previous studies observed that SNP-metabolite associations might be different between women and men, 
we analyzed SNP-by sex interactions (Fig. 1). Although two variants indicated significant interaction with sex in 
EPIC-Potsdam, these findings could not be confirmed in KORA F4 (Supplementary Table S6).
The relation of the identified SNPs with the metabolic network structures is depicted in Fig. 2.
Biologic pathway annotations. Not all variants could be linked to specific pathways within the KEGG 
database (Supplementary Table S7). However, with regard to the annotated gene functions plausible metabolic 
pathways were found for most variants. For example, FADS1 and FADS2 were linked to “Biosynthesis of unsatu-
rated fatty acids” and FADS2 was associated with “alpha-Linolenic acid metabolism” and “PPAR signalling path-
way”. MOGAT2 was connected to “Glycerolipid metabolism” and “Fat digestion and absorption”.
Gene-based analyses identified four genes associated with metabolite traits. Single SNP anal-
yses of low-frequency and rare variants are usually considered underpowered in studies of moderate sample 
size like ours13. Therefore, we conducted two gene-based analyses to enhance the power of our study (Fig. 1). 
We identified ten genes associated with metabolite traits in SKAT or burden tests (Supplementary Table S8). 
However, only three genes (GFRAL, BIN1, TFRC) showed nominal significant associations (P < 0.05) with 
metabolite traits within KORA F4 (Table 2). The association for GFRAL included three low-frequency variants 
(rs147652095, rs115053739, rs146300118; all with MAF = 1.8%) while BIN1 and TFRC included only common 
variants (Supplementary Table S9). In a second step, we considered functional annotation and restricted the 
gene-based analysis to those exome chip variants which are predicted to be damaging (see Methods section). This 
analysis revealed six different genes in EPIC-Potsdam (Supplementary Table S10) of which, only one (OR51Q1) 
including two low-frequency variants (rs151161477 with MAF = 1.21% and rs58283839 with MAF = 1.57%) 
(Supplementary Table S11) was replicated in within KORA F4 (Table 2). By excluding the top variants from the 
gene-based analyses (see Methods section) we found that multiple low-frequency variants within GFRAL are 
involved within the association, while in OR51Q1, the association is driven by the top low-frequency variant 
(rs58283839) (Supplementary Table S12). However, none of the single SNPs within the genes was significantly 
associated with metabolite traits individually (Supplementary Tables S9 and S11).
Identified genetic variants were weakly associated with risk of type 2 diabetes and other traits. 
Among the genes identified to be associated with diabetes-related metabolite traits by gene-based analyses, none 
was associated with type 2 diabetes in gene-based analyses (Supplementary Table S13).
Based on the single SNP analyses, 16 independent loci could be identified from the candidate SNP analyses 
and exploratory analyses (Fig. 1).
None of the 16 SNPs associated with diabetes-related metabolic traits (predicted functions are summa-
rized in Supplementary Table S14) was additionally associated with type 2 diabetes within the EPIC-Potsdam 
study (Table 3). Nevertheless, nine of them (rs541503 (PHGDH), rs715 (CPS1), rs272893 (SLC22A4/OCTH1), 
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rs9393903 (ELOVL2), rs3204953 (REV3L), rs603424 (SCD), rs174550 (FADS1), rs499974 (MOGAT2), rs7157785 
(SGPP1)) showed nominally significant association with diabetes in published data from bigger GWAS consor-
tia for type 2 diabetes (up to 110.452 individuals) or exome array analyses (up to 75.670 individuals) of which 
two (rs174550 (FADS1) and rs3204953 (REV3L)) were significant after correction for multiple testing by FDR 
(Table 3). For only four out of the nine variants (rs541503 (PHGDH), rs715 (CPS1), rs603424 (SCD), rs499974 
(MOGAT2)) the expected effect was directional consistent with the one which was actually observed within the 
DIAGRAM consortium or the GoT2D consortium2, 14, resulting in a directional consistency of 44.4% (P = 1) 
in the binomial test. In addition to the association with type 2 diabetes, one variant (rs174550 (FADS1)) was 
significantly associated with fasting glucose based on a large-scale meta-analysis of the MAGIC (n = 58.074)15 
and two (rs715 (CPS1), rs1136001 (NTAN1)) were significantly associated with BMI within large-scale GWAS 
meta-analysis of the GIANT consortium (n = 253.288)16 (Table 3).
Discussion
Within this study, we investigated the contribution of genetic variants on diabetes-related metabolic traits to get 
a deeper insight into the underlying biological processes and to identify novel risk variants for this polygenic 
disease. We tested findings from previous GWAS and found associations with diabetes-associated metabolites for 
variants located in FADS1, ELOVL2, PLEKHH1, SPTLC3, ACSL1, SCD, SLC22A4, OCTN1, PHGDH7; CPS1 and 
PAH8. Furthermore, our exploratory analysis identified additional genetic variants from the exome chip, which 
were located in REV3L, PNLIPRP2, NTAN1, APOE, MOGAT2, and SGPP1 and of which one locus (MOGAT2) 
was novel for metabolite traits.
Using diabetes-associated metabolites as intermediate phenotypes provides the possibility to investigate bio-
markers which are more proximal to genes and biological pathways than complex disease endpoints, ensuring 
higher statistical power to detect genetic associations6.
To deal with multiple testing issues, we selected a reduced panel of metabolite traits using their already pub-
lished network structure17. This approach further reduces the number of outcomes to be tested compared to 
studies which used all possible ratios - independent of their correlation structure. Although varying heritability 
estimates have been found for the analyzed diabetes-associated metabolites traits ranging from low (h2 = 3%) for 
phenylalanine18 to moderately to high (33% ≤ h2 ≤ 59%)18 or even higher e.g. glycine (h2 = 70%)19, individual 
metabolic profiles are long-term conserved20, supporting their suitability for studying pathways underlying dis-
ease development.
Despite the smaller sample size in our study compared to one meta-analysis which analyzed Biocrates metabo-
lites in 7,478 individuals9, we identified one novel locus rs499974 (MOGAT2) which was related to a ratio between 
Metabolite 
trait Chr
SNPb 
(Locus)
EPIC-Potsdama KORA F4 pooled
Replicated e
Consequence 
(GRCH37)
scaled 
CADD 
scorenc
allele 
frequency 
(coded allele)
Beta 
(SE)d p nc
allele 
frequency 
(coded allele)
Beta 
(SE)d p Beta (SE) d p
PC aa C42:1/ 
PC aa C42:0 1
rs41282492 
(CHIA) 2190 87.9 (A)
0.25 
(0.05)
1.01 
E-07 2692 87.8 (A)
−0.09 
(0.04)
2.78 
E-02 0.08 (0.17)
6.41 
E-01 Asn45Asp 0.01
Tyrosine/ 
Methionine 6
rs3204953 
(REV3L) 2201 85.2 (C)
−0.28 
(0.04)
9.80 
E-12 2689 84.0 (C)
−0.20 
(0.03)
1.49 
E-09
−0.24 
(0.04)
7.45 
E-09 * Val3064Ile 32
PC aa C36:1/ 
PC aa C34:1 10
rs10885997 
(PNLIPRP2) 2201 58.8 (A)
−0.17 
(0.03)
5.54 
E-08 2692 58.6 (A)
−0.09 
(0.02)
1.70 
E-05
−0.13 
(0.04)
1.46 
E-03 *
Synonymous 
variant 7.74
PC aa C40:5/ 
PC aa C38:5 11
rs499974 
(MOGAT2) 2203 81.2 (C)
−0.21 
(0.04)
2.25 
E-08 2692 81.3 (C)
−0.18 
(0.03)
6.97 
E-08
−0.19 
(0.03)
6.88 
E-15 *
downstream 
gene variant 8.66
PC ae C44:6/ 
PC aa C42:1 11
rs10790162 
(BUD13) 2203 6.70 (A)
−0.32 
(0.06)
1.57 
E-07 2691 7.56 (A)
−0.06 
(0.05)
2.51 
E-01
−0.19 
(0.13)
1.53 
E-01 intron variant 6.55
SM C16:1/ PC 
aa C28:1 14
rs7157785 
(SGPP1) 2203 83.6 (G)
0.49 
(0.04)
1.45 
E-35 2691 82.6 (G)
0.40 
(0.03)
2.27 
E-40 0.45 (0.04)
2.39 
E-24 *
regulatory 
region variant 1.91
SM (OH) 
C22:2/ SM 
C24:0
14 rs7157785 (SGPP1) 2203 83.6 (G)
−0.22 
(0.04)
5.46 
E-10 2692 82.6 (G)
−0.24 
(0.03)
6.40 
E-15
−0.23 
(0.02)
9.22 
E-24 *
regulatory 
region variant 1.91
SM (OH) 
C22:2/ SM 
(OH) C14:1
14 rs7157785 (SGPP1) 2202 83.6 (G)
0.42 
(0.04)
2.79 
E-27 2692 82.6 (G)
0.37 
(0.03)
4.21 
E-28 0.40 (0.03)
7.09 
E-55 *
regulatory 
region variant 1.91
SM (OH) 
C22:2/ SM 
(OH) C22:1
14 rs7157785 (SGPP1) 2202 83.6 (G)
−0.30 
(0.04)
6.00 
E-15 2691 82.6 (G)
−0.27 
(0.03)
9.89 
E-17
−0.28 
(0.02)
7.52 
E-31 *
regulatory 
region variant 1.91
19 rs7412 (APOE) 2202 91.4 (C)
−0.27 
(0.05)
1.30 
E-07 2688 91.5 (C)
−0.14 
(0.04)
1.76 
E-03
−0.20 
(0.06)
1.48 
E-03 * Arg202Cys 30
PC aa C36:3/ 
PC aa C34:3 16
rs1136001 
(NTAN1) 2201 67.0 (G)
0.18 
(0.03)
5.58 
E-09 2690 69.0 (G)
0.14 
(0.03)
3.29 
E-07 0.16 (0.02)
1.18 
E-14 * His283Asn 0.81
Table 1. Exome chip variants associated with metabolite traits at suggestive significance in EPIC-Potsdam and 
replication in KORA F4. Chr, chromosome; SE, standard error; CADD, Combined Annotation Dependent 
Depletion. aonly sub-cohort; bgene variants are reported on the forward strand of NCBI build 37; cmetabolite 
outliers (±4SD) were excluded; dmetabolites (µmol/L) were ln-transformed and standardized, effect estimates 
are adjusted for age and sex; esignificance threshold: 0.05/11 tests = 4.55 × 10−3.
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two diacyl-phosphatidylcholines (PC aa C40:5 and PC aa C38:5). This variant was previously mainly shown 
to be associated with lipid traits (HDL-c, total cholesterol, triglycerides)21. Probably due to the limited power 
of our analysis, none of the single SNP findings could be related to incident type 2 diabetes in EPIC-Potsdam. 
Nevertheless, two SNPs (FADS1, REV3L) which were associated with metabolite traits were significant in bigger 
Figure 2. Network structure of metabolites within EPIC-Potsdam and related genetic variants. 34 diabetes 
associated metabolites are depicted in grey elipses; sixteen identified genetic variants associated with diabetes-
related metabolite traits are depicted in red rectangles (only the top associated metabolite trait is depicted for 
each locus); solid line indicates direct association between metabolites; dashed line indicates inverse association 
between metabolites; GGM network was adapted from the publication by A. Floegel et al.53 and drawn by using 
Cytoscape Software v3.2.166.
Metabolite 
trait Gene
EPIC-Potsdama KORA F4a
Nr. of 
common 
variantsb
Nr. of 
rare 
variantsb PSKAT-C Pburden-C
Nr. of 
common 
variantsb
Nr. of 
rare 
variantsb PSKAT-C Pburden-C
Replicated 
in KORA 
F4 
(p < 0.05)
PC aa 
C42:1/PC 
aa C42:0
GFRAL 6 0 1.54E-05c 2.15E-06c 6 0 1.02E-02 4.32E-03 *
SM (OH) 
C22:2/SM 
C18:0
BIN1 2 0 7.98E-05c 1.50E-06c 2 0 1.96E-02 3.70E-01 *
SM (OH) 
C22:2/SM 
C16:1
TFRC 3 0 1.66E-06c 7.53E-04c 3 0 2.30E-02 9.08E-02 *
H1 OR51Q1d 2 1 8.85E-06e 9.62E-06e 2 1 1.47E-02 1.38E-02 *
Table 2. Gene-based association with metabolite traits using SKAT and burden test in EPIC-Potsdam and 
replicated in KORA F4. aEPIC-Potsdam: n = 2200–2202, KORA F4: n = 2688–2692; analyses were adjusted for 
age and sex. bRare variants with MAF ≤ 
n
1
2
 (≤0.015 EPIC-Potsdam or ≤0.014 KORA F4). cSignificance threshold was 
defined as P < 0.05/[number of genes with >1 variants (ranging from 7243 to 7332)] = 6.8 × 10−6 to 6.9 × 10−6. 
dIdentified by restricting the analysis on potentially damaging variants. eSignificance threshold was defined as 
P < 0.05/[number of genes with >1 variants (ranging from 1449 to 1492)] = 3.4 × 10−5 to 3.5 × 10−6.
www.nature.com/scientificreports/
6SCIENTIFIC RepoRtS | 7: 6037 | DOI:10.1038/s41598-017-06158-3
consortia for type 2 diabetes, such as DIAGRAM2 or GoT2D14. Furthermore, according to data from the MAGIC 
consortium15, FADS1 was related to fasting glucose. In addition, we show that the rs174550 (FADS1) is stronger 
related to metabolite traits than the previously known mGWAS hit (rs174547; LD with rs174550: r² = 1; D’ = 1) 
and remained significantly associated with a ratio of phosphatidylcholines in analyses containing both SNPs. On 
Chr SNP Locus
MAF 
in % 
(minor 
allele) n (ncases)
Model 
1 HR 
(95% 
CI)
Model 
2 HR 
(95% 
CI)
Observed 
association for 
type 2 diabetes 
OR (p-value)a
Expected 
direction of 
the diabetes 
association h
Match 
between 
expected 
and 
observed 
direction
Association fasting 
glucose:  beta 
(p-value)a
Association 
BMI: beta 
(p-value)a
1 rs541503 PHGDH 37.5 (C) 2893 (753)
0.92 
0.81–
1.04)
0.91 
(0.78–
1.06)
0.89 (0.039)b ↓ yes −0.003 (0.481) −0.004 (0.330)
2 rs715 CPS1 30.1 (C) 2886 (749)
0.98 
(0.86–
1.12)
0.93 
(0.79–
1.08)
0.94 (0.035)c ↓ yes 0.007 (0.276) 0.022 (7.13E-06*)
4 rs12641551 ACSL1 31.9 (G) 2891 (758)
1.02 
(0.90–
1.17)
1.02 
(0.88–
1.18)
0.90 (0.104)b ↓ yes — —
5 rs272893 SLC22A4, OCTN1 38.4 (A) 2891 (758)
1.02 
(0.90–
1.15)
1.11 
(0.97–
1.27)
0.93 (0.041)d ↓ yes −0.008 (0.040) 0.004 (0.269)
6 rs9393903 ELOVL2 24.5 (A) 2932 (763)
0.99 
(0.86–
1.15)
0.98 
(0.83–
1.16)
0.97 (0.040)e ↑ no 0.001 (0.816) 0.004 (0.350)
6 rs3204953 REV3L 14.7 (A) 2891 (758)
0.94 
(0.78–
1.12)
0.94 
(0.76–
1.18)
0.88 (0.0008*)c ↑ no −0.007 (0.199) −0.002 (0.640)
10 rs603424 SCD 18.7 (A) 2892 (759)
1.06 
(0.91–
1.24)
0.99 
(0.82–
1.19)
1.07 (0.047)c ↑ yes 0.010 (0.083) −0.002 (0.733)
10 rs10885997 PNLIPRP2 41.2 (G) 2891 (758)
0.96 
(0.85–
1.09)
1.01 
(0.88–
1.16)
1.04 (0.259)d ↑ yes 0.001 (0.787) 0.0004 (0.9203)
11 rs174550 FADS1 33.5 (G) 2891 (758)
0.93 
(0.82–
1.06)
0.98 
(0.85–
1.13)
0.95 (0.003*)f ↑ no −0.021 (1.48E-8*) 0.003 (0.426)
11 rs499974 MOGAT2 18.9 (A) 2891 (758)
1.14 
(0.97–
1.34)
1.07 
(0.89–
1.28)
1.03 (0.034)e ↑ yes 0.002 (0.716) −0.006 (0.140)
12 rs1718306 PAH 39.9 (T) 2902 (754)
1.01 
(0.89–
1.15)
0.91 
(0.78–
1.05)
1.04 (0.13)c ↑ yes 0.004 (0.273) 0.004 (0.357)
14 rs7156144 PLEKHH1 42.5 (A) 2860 (744)
1.10 
(0.96–
1.25)
1.06 
(0.92–
1.23)
1.04 (0.097)c ↑ yes −0.003 (0.506) 0.001 (0.842)
14 rs7157785 SGPP1 16.4 (A) 2891 (758)
1.05 
(0.90–
1.23)
1.08 
(0.90–
1.30)
1.04 (0.029)e ↓ no 0.011(0.047) 0.002 (0.767)
16 rs1136001 NTAN1 33.1 (A) 2891 (758)
0.89 
(0.78–
1.01)
0.89 
(0.77–
1.04)
0.98 (0.083)e ↓ yes −0.001 (0.903) −0.013 (0.002*)
19 rs7412 APOE 8.60 (A) 2891 (758)
1.08 
(0.87–
1.33)
0.93 
(0.72–
1.21)
1.09 (0.371)d ↓ no — 0.018 (0.075)
20 rs364585 SPTLC3 38.1 (A) 2891 (758)
0.91 
(0.81–
1.03)
1.04 
(0.90–
1.20)
0.95 (0.169)g ↑ no −0.004 (0.239) −0.003 (0.401)
Table 3. HRs (95% CI) for type 2 diabetes of genetic variants in EPIC-Potsdam and look-up in other consortia 
for type 2 diabetes, fasting glucose and BMI. SNP, single nucleotide polymorphism; Chr, chromosome; MAF, 
minor allele frequency; HR, hazard ratio; CI, confidence interval; OR, odds ratio. Only genetic variants which 
could be replicated within KORA F4 were included. Model 1 is stratified for age at baseline and adjusted for sex; 
Model 2 is further adjusted for waist circumference. aResults for type 2 diabetes were looked up at http://www.
type2diabetesgenetics.org on the 21.07.201614; beta estimates for fasting glucose are from MAGIC GWAS data15; 
beta estimates for BMI are from GIANT GWAS data16, strongest type 2 diabetes association reported within: 
bGoT2D WGS, cGoT2D WGS + replication, dGWAS SIGMA, eDIAGRAM, f82k exome chip, gSIGMA exome 
chip analysis. hExpected direction was defined based on the sign of the product between the SNP-metabolite 
trait association and the metabolite trait-type 2 diabetes association (using cox-regression models adjusted for 
age and sex); ↑ Indicates a positive association, ↓ Indicates an inverse association. *Significant after correction 
for false discovery rate62.
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a functional level, we cannot consider one or another as being more relevant for diabetes risk as the CADD scores 
are low for both variants (rs174550: CADD = 3.57; rs174547: CADD = 6.23). A recent study identified a func-
tional multiallelic variant (rs174557; LD with rs174550: r² = 0.778; D′ = 1) located in an AluYe5 element in intron 
1 of FADS1 which affects two transcription factor binding sites with opposing effects on FADS1 expression22. This 
newly described variant may represent the causal variant at the FADS1 locus. The FADS1-2 locus is linked to fatty 
acid metabolism and biosynthesis of unsaturated fatty acids. Fatty acids itself as well as the fatty acid desaturases 
which catalyse the desaturation of fatty acids are known to be associated with type 2 diabetes risk23. Variants 
within FADS1 and FADS2 encoding the fatty acid Δ5 desaturase and Δ6 desaturase, respectively, are located in a 
gene family (FADS1-2-3) and belong to the most frequently identified mGWAS hits in previous studies showing 
associations with levels of phosphatidylcholines and sphingolipids6, 7, 24. In EPIC-Potsdam, the minor allele of 
the variant rs174546 within FADS1 (LD with present FADS1 variant rs174550: r² = 1; D = 1) was associated with 
lower Δ5 desaturase and Δ6 desaturase activity23. While a genetically-determined higher Δ5 desaturase activity 
tended to be associated with lower type 2 diabetes risk after adjustment for the other estimated desaturase activity, 
a genetically-determined high Δ6 desaturase activity was significantly associated with higher risk23. As this gene 
cluster is characterized by high LD, it is difficult to assign effects of single genetic variants located at this locus 
to one or another desaturase activity. Therefore, observed associations for FADS1 in the present study might be 
attenuated by confounding by LD of FADS2 and vice versa.
The second finding was a missense variant REV3L (rs3204953, encoding p. Val3064Ile) belonging to the 0.1% 
most deleterious variants within the human genome (CADD = 32.0)25 which was associated with a ratio between 
tyrosine and methionine and showed significant association with type 2 diabetes in databases after correction for 
multiple testing. While this variant is common among Europeans (MAF = 17%), it is rather rare in other popula-
tions: Africans (MAF = 0.005), East Asians (MAF = 0.001)26.
According to the PhenoScanner database27, rs3204953 was associated with alanine to tyrosine ratio 
(p = 2.98 × 10−11)28, schizophrenia (0.07 for the effect allele (T); p = 2.14 × 10−5)29 and age at menopause 
(beta = 0.15 for the effect allele (T); p = 1.10 × 10−7)30 in previous GWAS. The latter trait is itself related to type 
2 diabetes31. On the one hand, factors such as sex-hormones are discussed in this context32, on the other hand, 
early menopause might represent a marker for premature aging31 as it has been related to DNA damage repair30. 
In this context, REV3L encoding the REV3L (REV3 Like, DNA Directed Polymerase Zeta Catalytic Subunit), a 
specialized DNA polymerase33, was linked to the Fanconi anemia pathway in the KEGG database representing an 
essential pathway for the DNA repair of interstrand cross-links34. More specifically, this enzyme is involved in the 
translesion DNA synthesis, one essential step within the Fanconi anemia pathway, which represents one of the 
cellular mechanisms for DNA damage tolerance or post-replication repair34. For example, Singh et al. could show 
that the human REV3L maintains the integrity of the mitochondrial genome by affecting the mtDNA metabolism 
and that inactivation of Rev3 leads to mitochondrial dysfunction35. There is quite some evidence that DNA dam-
age induced by oxidative stress is relevant in type 2 diabetes and might additionally represent a mechanistic link 
with cancer36; however, whether genetic markers in REV3L might play a role in this context needs to be studied.
We applied gene-based tests which have been shown to be better powered than single variant analyses13 and 
a decreased number of tests is carried out by grouping variants based on genes. In these analyses, we identified 
associations between metabolite outcomes and four genes (GFRAL, BIN1, TFRC and OR51Q1). However, none 
of the identified genes was linked to type 2 diabetes; neither in EPIC-Potsdam nor in previous studies. Although 
we found associations with the genes and metabolite traits, it is striking that none of the single variants located in 
the genes showed any association with the metabolites of interest which further impedes interpretation. Another 
issue is that compared to our single SNP findings, replication of the gene-based results in KORA F4 was less 
successful and some of the replicated genes included only common variants. Although, we checked the allele 
frequencies between both cohorts; still, some minor differences might have affected the gene-based results.
Even though our study identified some interesting candidates which were linked to relevant pathways of type 
2 diabetes, all identified SNPs in the single SNP analysis were common variants and no low-frequency or rare 
variants were identified, which is plausible due to the limited power of our analysis.
In general, SNPs can be used to assess the causality of observed associations between biomarkers and complex 
traits such as type 2 diabetes by Mendelian Randomisation studies. However, Mendelian randomisation studies 
rely on a number of assumptions of which one is that “the genotype is associated with the outcome through the 
studied exposure only”37 or simply said that there are no pleiotropic effects of the SNP. However, many of the 
variants in our study, e.g. FADS1, SPTLC3 and APOE were associated with different metabolite traits in addition 
to other biomarkers of lipid metabolism. The observational design of our study does not allow to discriminate if 
those different effects are all in a causal chain or related via independent physiological mechanisms. Therefore, 
we did not investigate causal SNP effects of the analysed genetic variants and type 2 diabetes by Mendelian 
Randomization. However, if we compare our observations to the assumptions of Mendelian randomization, we 
have to acknowledge that our observations would be more in line with a non-causal relationship between specific 
metabolites such as certain ratios of diacyl-phosphatidylcholines (PC aa C36:3/PC aa C36:4 or PC aa C38:3/PC 
aa C38:4) and tyrosine to methionine ratio and type 2 diabetes, since expected and observed effect direction were 
inconsistent for SNPs in FADS1 and REV3L. Similarly, a recent study5 found inconsistent effect directions for two 
of four nominal significant variants in DIAGRAM data1 using intermediate metabolite traits to determine an 
expected direction of the SNP-diabetes association. However, with regard to FADS1, we have only tested the most 
significant metabolite ratios for their association with type 2 diabetes. Hence, other significant ratios might show 
diabetes associations with directional consistency.
In summary, we identified a novel metabolite locus (MOGAT2) in single variant analyses and four genes 
(GFRAL, BIN1, TFRC, OR51Q1) within gene-based tests and could show that two previously known mGWAS 
loci (FADS1 and REV3L) might be relevant for the risk of type 2 diabetes. Our findings do not clearly support the 
idea that specific diabetes-associated metabolite ratios (PC aa C36:3/PC aa C36:4, PC aa C38:3/PC aa C38:4 and 
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tyrosine/methionine) may be causal traits for type 2 diabetes, but rather show that shared genetic influences on 
diabetes-related metabolite traits and type 2 diabetes itself exist.
Materials and Methods
Study population. EPIC-Potsdam study. The European Prospective Investigation into Cancer and 
Nutrition (EPIC)-Potsdam study consists of 27,548 participants recruited between 1994 and 1998 from the 
general population in Potsdam and surroundings38. The baseline examination involved a personal interview 
including questions on prevalent diseases, a self-administered questionnaire on socio-economic and lifestyle 
characteristics, interviewer-conducted anthropometric measurements and a blood sample collection39. We used a 
prospective case-cohort nested within the EPIC-Potsdam study, described in detail previously40. Briefly, a sub-co-
hort of 2,500 individuals was randomly selected from 26,444 participants who provided blood samples at base-
line. Additionally, 849 incident type 2 diabetes cases were identified in the full cohort of whom 820 cases provided 
blood samples (Supplementary Fig. S1).
Participants with missing or implausible data on metabolite measurements (described in detail within 
the metabolite measurements section), prevalent diabetes, or participants with uncompleted follow-up were 
excluded, leaving 2283 individuals for analyses in the sub-cohort. Similar exclusion criteria were applied for type 
2 diabetes cases, leaving 784 incident cases for analysis. Because the sub-cohort is representative of the full cohort 
at baseline, the sub-cohort included 73 individuals who developed incident type 2 diabetes during follow-up. 
Exclusions due to missing genotype data or outlying metabolite values were done separately in each analysis.
Cooperative Health Research in the Region of Augsburg study (KORA F4). KORA (Cooperative Health Research 
in the Augsburg Region) is a research platform of independent population-based health surveys and subsequent 
follow-up examinations of community-dwelling adults living in the region of Augsburg in Southern Germany. 
Study design, sampling method and data collection have been described in detail elsewhere41. The KORA S4 
survey (1999 to 2001) comprised 4,261 participants, 25 to 74 years old42. Of these, 3,080 subjects participated in 
the follow-up examination KORA F4 (2006 to 2008)43. The present study is based on a subsample of 2,818 partic-
ipants of KORA F4 with Biocrates metabolomics data available.
Ethics statement. All participants provided written informed consent. The EPIC-Potsdam study was approved 
by the ethics committee of the State of Brandenburg, Germany and the KORA study was approved by the ethics 
committee of the Bavarian medical association, Germany. All procedures were in accordance with the ethical 
standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its 
later amendments or comparable ethical standards.
DNA-extraction, genotyping and quality control. EPIC-Potsdam. The DNA has been extracted 
from buffy coats using the chemagic DNA Buffy Coat Kit special on a Chemagic Magnetic Separation Module I 
(PerkinElmer Chemagen technologies, Baesweiler, Germany) according to the manufacturer’s manual.
The selection of candidate SNPs (Supplementary Table S15) was based on previous studies available from the 
literature which were conducted within the KORA F4 study7, 8. Illig et al.7 reported 15 GWAS hits for metabolite 
traits which showed associations with the 14 diabetes-associated metabolite traits from EPIC-Potsdam. However, 
one finding from Illig et al.7 (rs7094971; SLC16A9) which was exclusively associated with phenylalanine levels 
and showed only a small explained variance in the linear model of 0.10 was not selected for our analysis. As Shin 
et al.8 found a stronger candidate for glycine levels, the hit reported by Illig et al.7 (rs2216405; CPS1) was replaced 
by the SNP rs715 (CPS1). Additional five candidates for glycine (n = 4) and phenylalanine (n = 1) levels were 
selected from Shin et al.8 based on a predefined significance threshold of <10−6. If more than one SNP was associ-
ated on a specific locus, the one showing the lowest p-value while considering LD structures between the variants 
was selected. By doing so we ended up with 19 candidate SNPs for the present analysis. If neither the respective 
variant nor a proxy SNP was present on the exome chip, the variants were genotyped within EPIC-Potsdam by 
KBioscience¸ Teddington, UK (http://www.kbioscience.co.uk) using KASP SNP genotyping system.
The Illumina HumanExome v1.1 Bead Array44 was used for genotyping of type 2 diabetes cases and the 
sub-cohort. Genotyping was performed in the Life and Brain Center in Bonn, Germany. Genotype calling and 
quality control (QC) were carried out using Illuminas GenomeStudio v2011.1 software suite. To improve gen-
otype calling, all single nucleotide variants were re-clustered based on a cluster file from genotyping of 23000 
women in the Women’s Genome Health Study45 genotyped with the Illumina HumanExome v1.1 Bead Array. 
This cluster file was generated according to the CHARGE Best Practices and Joint Calling Protocol, which was 
also used to derive the final dataset46. To improve the genotype calling for rare variants zCall with a threshold of 
8 was applied47. Individuals with low call rate, discordant sex information (F value between 0.2 and 0.8), related 
or duplicated individuals (IBD > 0.185) and individuals with divergent ancestry were excluded from further 
analysis.
KORA F4. DNA was extracted from 9 ml EDTA-blood as described elsewhere48. Genotyping was done using 
the Illumina HumanExome v1.0 Bead Array, calling was carried out according to the CHARGE Best Practices 
and Joint Calling Protocol46.
Metabolite measurements in EPIC-Potsdam and KORA F4. Metabolite quantification of both stud-
ies, EPIC-Potsdam and KORA F4, was performed in the Genome Analysis Center at the Helmholtz Zentrum 
München. All samples have been measured using the AbsoluteIDQTM p150 Kit (Biocrates Life Sciences AG, 
Innsbruck, Austria) in combination with flow injection analysis-tandem mass spectrometry (FIA-MS/MS). 
Serum samples of 10 µL serum were used to quantify 163 simultaneously, including 41 acylcarnitines (Cx:y), 
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14 amino acids, hexose (sum of six-carbon monosaccharides without distinction of isomers), 92 glycerophos-
pholipids (lyso-, diacyl-, and acyl-alkylphosphatidylcholines), and 15 sphingomyelins. The method for sample 
preparation and measurement as well as the metabolite denomination was previously described in full detail49. 
All samples of EPIC-Potsdam have been processed in one batch50. The KORA F4 samples have been meas-
ured in three batches of approximately 1000 samples at three different time points with a recalibration of the 
equipment in between7, 51; therefore, all analyses calculated in KORA were further adjusted for batch effects. 
Metabolites showed an overall good reliability over a 4-month period, with a median intraclass correlation coef-
ficient of 0.5750. To ensure valid measurements, metabolites below the limit of detection (n = 30) and those with 
very high analytical variance (n = 6) were excluded, resulting in 127 metabolites50. For the present analysis 34 
diabetes-associated metabolites and 2 metabolic factors were selected12. Previous studies could show that the 
usage of metabolite ratios compared to single metabolites provides higher statistical power to detect significant 
associations with genetic variants52. Therefore, we selected all metabolite ratios out of the 34 diabetes-associated 
metabolites which were connected via one edge17 based on a metabolite network within EPIC-Potsdam build by 
Gaussian graphical modeling (Fig. 1)53. We included all single metabolites and 2 metabolites factors which were 
independently associated with type 2 diabetes (Fig. 1)12. Therefore, our analysis (Fig. 1) included 106 outcomes 
referred to as diabetes-related metabolite traits consisting of 90 metabolite ratios, 14 single metabolites and 2 
metabolite factors = (list of metabolite traits in Supplementary Table S16).
Assessment of type 2 diabetes in EPIC-Potsdam. Systematic information sources for incident cases 
were self-reports of a type 2 diabetes diagnosis, type 2 diabetes-relevant medication, and dietary treatment due 
to type 2 diabetes during follow-up. Furthermore, we obtained additional information from death certificates or 
from random sources, such as the tumor centers, physicians, or clinics that provided assessments from other diag-
noses. Although self-reports of type 2 diabetes were generally reliable, by including other sources of information, 
we even improved the completeness of case ascertainment. Once a participant was identified as a potential case, 
disease status was further verified by sending a standard inquiry form to the treating physician. Only physician- 
verified cases with a diagnosis of type 2 diabetes (International Classification of Diseases, 10th revision code: E11) 
and a diagnosis date after the baseline examination were considered confirmed incident cases of type 2 diabetes.
Statistical analysis. All data analyses were performed by using the software packages Statistical Analysis 
System (SAS) Enterprise Guide 6.1 with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), PLINK v1.0754 and 
R (version 3.1.0 (2014-04-10)).
Candidate analysis of known mGWAS hits. We selected 19 candidate SNPs that showed associations with dia-
betes associated metabolites in previously published mGWAS of metabolic traits (Fig. 1). Associations of the 
selected candidate SNPs (list in Supplementary Table S15)7, 8 with metabolite traits were investigated within the 
sub-cohort via linear regression models (additive genetic model; per copy of the minor allele) adjusted for age 
and sex using SAS version 9.4. Metabolite traits (except metabolite factors) were natural log-transformed to nor-
malize the right-skewed distributions. After ln-transformation metabolite outliers of >4SD from the mean were 
excluded and metabolite traits were standardized (mean = 0; SD = 1). Correction for multiple testing was done by 
the Bonferroni method [significance threshold: 0.05/(19 × 61 independent metabolite traits) = 4.31 × 10−5]. The 
effective number of independent metabolite traits of 61 out of 106 was determined by using equation 5 of Li and 
Ji 200555 which is included in the matSpD R script available onlin56, 57.
Exploratory analysis. Exploratory single variant association analysis was performed in PLINK v1.0754 and 
included all exome chip variants with MAF ≥ 0.005 (n~42,000 markers) as exposure and 106 metabolite traits 
defined above as outcome (Fig. 1). We considered a genomic control (GC) corrected p-value as exome chip-wide 
significant at P < 1.95 × 10−8 [ = 0.05/(42,000 polymorphic variants × 61 independent metabolite traits)]55. 
Suggestive significance threshold was defined as P < 1.64 × 10−7 [ = (1.00 × 10−5/61)]. Transformation of metab-
olite traits and outlier removal was identical to the replication analysis of previously identified mGWAS hits. We 
assumed an additive genetic model (per copy of the allele on the forward strand), adjusted for age at recruitment 
and sex. Identified SNPs with at least suggestive significance (P < 1.64 × 10−7) were replicated within the KORA 
study by applying the same linear models which were further adjusted for batch effects. Results for single variant 
analysis from EPIC-Potsdam and KORA F4 were pooled by meta-analysis using a random effects model with the 
R package meta58 and significance was defined by correcting for eleven test (P < 4.55 × 10−3). Analyses for the 
top associated metabolite traits were performed to check for independent signals at each locus [Y = β1 SNP1 + β2 
SNP2 (+β3 SNP3) + β4 age + β5 sex + n]. Independently associated SNPs were selected for the diabetes analysis.
Additionally, we performed an exploratory interaction analysis for sex by modeling linear regression models 
adjusted for age and sex and including an interaction term (Y = β1 SNP + β2 age + β3 sex + β4 (sex × SNP) + n). 
Interaction terms with P < 1.64 × 10−7 were considered as suggestively significant and attempted to replicate in 
KORA F4. Gene-based analyses were performed with the R package SKAT59. We applied the sequence kernel 
association test (SKAT-C) and burden-C test with the default options using “SKAT_CommonRare” function60 
to test for associations between common and rare genetic variants in a gene and 106 metabolite traits (Fig. 1). 
Models were adjusted for age and sex. Correction for multiple testing was done with the Bonferroni method [sug-
gestive significance threshold: 0.05/(number of genes with >1 variants (ranging from 7243 to 7332)) = 6.8 × 10−6 
to 6.9 × 10−6]. Additional analyses considering only variants annotated as potentially damaging (based on the 
annotation list from the CHARGE consortium: column “sc_damaging”) were conducted. Genes showing sug-
gestive significance in EPIC-Potsdam were replicated in KORA F4 considering p < 0.05 as replicated. Within 
genes including more than two variants (GFRAL, TFRC and OR51Q1), we removed the top variant(s) showing 
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the lowest p-values in pooled single variant analyses from the gene-based analyses. By repeating the SKAT and 
burden-C test we determined the impact of the top variant(s) on the gene-based statistical significance. Variants 
were mapped to Ensembl annotation version 84 (GRCh37)26 and files provided by the CHARGE consortium46 
were used for gene annotation.
Association with type 2 diabetes. We evaluated all replicated previously known and all novel exploratory iden-
tified genetic variants (n = 16) with regard to their association with type 2 diabetes risk within EPIC-Potsdam 
(Fig. 1). Associations between genetic variants and diabetes risk were evaluated in SAS version 9.4 using Cox 
regression modified for the case-cohort design according to the Prentice method61. Age was used as the under-
lying time scale in all Cox models, with entry time defined as the participant’s age at recruitment and exit time 
defined as the age at the end of follow-up based on the date of diagnosis, death, or return of the last follow-up 
questionnaire. The analysis was stratified for age at the baseline examination in one-year intervals. Cox models 
were further adjusted for sex and waist circumference.
Associations between the investigated SNPs and risk of type 2 diabetes as well as BMI and fasting glucose 
were looked up in the AMP-T2D Program14. This database provides information on genetic variants and their 
diabetes-association in consortia for type 2 diabetes using exome sequencing, exome arrays for low-frequency 
variants and arrays for common variants14. Additionally, GWAS meta-analysis results for 24 other traits are 
available14.
Correction for multiple testing was applied by using false discovery rate (FDR) according to Benjamini and 
Hochberg62. We defined the expected direction for the SNP-diabetes association based on the sign of the product 
between the SNP-metabolite trait association (e.g. rs3204953 (REV3L) → tyrosine/methionine) and the metab-
olite trait-type 2 diabetes association (e.g. tyrosine/methionine → type 2 diabetes risk). For the latter we selected 
either the metabolite trait showing the lowest p-value with the SNP or the one of the SNP-associated metabolite 
traits indicating significant association with type 2 diabetes risk adjusted for age and sex in EPIC-Potsdam. We 
tested for directional consistency between expected and observed direction by applying a binomial test in R.
Assessment of functionality of genetic variants. To estimate the relative pathogenicity of identified 
genetic variants, we used Combined Annotation Dependent Depletion (CADD) v1.325. This method integrates 
various annotations into a single measure (C score) for each genetic variant. The scaled C score ranges from 1 to 
99 and ranks each variant in the genome relative to all possible 8.6 billion substitutions in the human reference 
genome based on the formula −10 × log10 (rank/total number of substitutions)25.
Bioinformatics annotation of genes at metabolite-associated loci. All identified SNPs were sys-
tematically linked to genes using a flanking region of at least 500 kb. A “GWAS to pathway” workflow method63 
was then used to link these genes to potential pathways within the KEGG database64. We used the Taverna 
Workbench Bioinformatics 2.565 software to run the workflow.
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